- Merck KGaA‘s adjusted EBITDA for Q3 was €1.62 billion, which is a 12% increase year-over-year and surpassed estimates of €1.56 billion.
- The healthcare sector’s adjusted EBITDA was €836 million, exceeding estimates of €767.6 million.
- Life Science adjusted EBITDA was slightly below estimates at €646 million, against the forecast of €660.4 million.
- Electronics adjusted EBITDA came in at €235 million, which was below the estimated €246.7 million.
- Overall adjusted EBITDA margin improved to 30.7% from 27.9% year-over-year, beating the estimate of 29.2%.
- Healthcare adjusted EBITDA margin stood at 39.2%, above the estimate of 36%.
- Life Science adjusted EBITDA margin met expectations at 29.3%.
- Electronics adjusted EBITDA margin was slightly under the expectation at 25.5% against 25.8%.
- Total net sales were €5.27 billion, marking a 1.8% rise year-over-year, though slightly below the forecast of €5.35 billion.
- Healthcare net sales were €2.13 billion, a 3.2% increase year-over-year, just shy of the estimate of €2.14 billion.
- Bavencio sales dropped 2.7% year-over-year to €180 million, under the forecast of €193.5 million.
- Rebif sales decreased by 12% year-over-year to €154 million, slightly above the estimate of €149 million.
- Mavenclad sales increased by 18% year-over-year to €265 million, surpassing estimates of €257.4 million.
- Life Science net sales increased by 0.9% year-over-year to €2.21 billion, below the estimate of €2.26 billion.
- Electronics net sales rose 0.8% year-over-year to €923 million, under the forecast of €960.6 million.
- EBIT amounted to €1.10 billion, a 12% increase year-over-year and above the estimate of €1.08 billion.
- Adjusted EPS was €2.30, compared to €2.07 in the previous year and slightly above the forecast of €2.27.
- Merck KGaA still forecasts fiscal year 2024 sales to be between €20.7 billion and €22.1 billion, tending towards the lower half of this range.
- The company anticipates fiscal year 2024 adjusted EBITDA between €5.8 billion and €6.4 billion, trending around the mid-point.
- Fiscal year 2024 adjusted EPS is projected to be between €8.20 and €9.30, trending near the mid-point of this range.
A look at Merck KGaA Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 2 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Merck KGaA, a global pharmaceutical and chemicals company, presents a promising long-term outlook based on the Smartkarma Smart Scores. With a strong score of 4 in Growth and Momentum, the company is positioned well for future expansion and market performance. Its research focus on areas such as oncology, neurodegenerative diseases, and autoimmune conditions indicates a commitment to innovation and potential for sustained growth in these critical sectors. Additionally, Merck KGaA‘s score of 3 in both Value and Resilience suggests a solid foundation and ability to withstand market fluctuations, enhancing its overall attractiveness as an investment option.
While the Dividend score of 2 may indicate slightly lower returns in this aspect, the company’s diversified portfolio spanning across pharmaceuticals, chemicals, and various other sectors highlights its adaptability and revenue potential. Overall, Merck KGaA‘s Smartkarma Smart Scores point towards a favorable outlook for investors seeking a long-term investment with a company that demonstrates growth potential, resilience, and strong market momentum in the pharmaceutical and chemical industries.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
